Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120811 | 0.89 | ADRA1A (0.47) | ADRA1ASLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL1364317 | 0.79 | TAAR1 (0.41) | TAAR1HTR2AHTR2CHTR2BHCAR2 | |
| SCHEMBL29940424 | 0.78 | SLC6A3 (0.53) | ADRA1ASLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL1067433 | 0.78 | SLC6A3 (0.53) | ADRA1ASLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL1366932 | 0.77 | HTR3A (0.46) | ADRA1ASLC6A2SLC6A3TAAR1DRD2 | |
| SCHEMBL1366116 | 0.77 | SLC18A3 (0.45) | ADRA1ADRD2 | |
| SCHEMBL1367144 | 0.77 | SLC18A3 (0.45) | ADRA1ADRD2 | |
| SCHEMBL242194 | 0.77 | SLC18A3 (0.45) | ADRA1ADRD2 | |
| SCHEMBL3790814 | 0.75 | SLC6A3 (0.50) | ADRA1ASLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL3786501 | 0.75 | HDAC4 (0.52) | ADRA1ASLC6A2SLC6A3SLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE HOLDINGS CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9801877-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2017-02-09 | — | — | US | disclosed |
| US-9403775-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| EP-3020402-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Holdings Corporation (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-1622569-B1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-8637497-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2617419-A1 | Aza spiro alkane derivatives as inhibitors of metallproteases | Incyte Corporation (US) | 2013-07-24 | — | — | EP | disclosed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1902717-A2 | Vasopressin antagonist and oxytocin antagonist | Otsuka Pharmaceutical Company, Limited (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0620003-B1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMA CO LTD (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-5753644-A | Vasopressin antagonist and oxytocin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5622947-A | VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ADRA1A 326/4885SLC6A2 3396/4885SLC6A3 1944/4885 |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | MMP9, MMP3, MMP12 | ADRA1A 1926/4885SLC6A2 3825/4885SLC6A3 3734/4885 |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADRA1A 1926/4885SLC6A2 3825/4885SLC6A3 3734/4885 |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | ADRA1A 1926/4885SLC6A2 3825/4885SLC6A3 3734/4885 |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADRA1A 1926/4885SLC6A2 3825/4885SLC6A3 3734/4885 |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADRA1A 1926/4885SLC6A2 3825/4885SLC6A3 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.